GlassScriptPhysician profile
Melissa A Michelon
NPI 1982983235
$4,175.87
in general payments reported to CMS, 2019-2025
20 companies · $1,720 in 2025
The $1,720 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $83.74 · 2022: $347 · 2023: $347 · 2024: $1,567 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,454 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,454.04 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $965.94 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| E.R. Squibb & Sons, L.L.C. | $757.52 | 2022-2025 | Sotyktu |
| Abbvie INC. | $593.18 | 2019-2025 | |
| Galderma Laboratories, L.P. | $386.70 | 2020-2025 | Nemluvio |
| Lilly USA, LLC | $313.76 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $257.00 | 2023-2025 | Otezla, Otezla |
| Allergan, INC. | $221.56 | 2022 | |
| Ucb, INC. | $121.68 | 2019-2024 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $110.95 | 2023-2025 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $104.46 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $71.37 | 2019-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $57.49 | 2024-2025 | Zoryve |
| Organon LLC | $54.90 | 2025 | Vtama |
| Biofrontera INC. | $29.42 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Genzyme Corporation | $29.11 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $28.62 | 2025 | Anzupgo |
| Verrica Pharmaceuticals INC. | $22.79 | 2024 | Ycanth |
| Merz North America, INC. | $18.79 | 2023 | Xeomin |
| Solta Medical, A Division of Bausch Health US, LLC | $16.64 | 2024 | Clear+Brilliant |
| Botanix Sb INC | $13.99 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Michelon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.